AzTrials
AzTrials

Strength Training AdaptationsNCT07803068

The Impact of 12-week Ashwagandha Supplementation Induced by Resistance Training on Strength, Levels of Neurotrophic and Stress Response Proteins, Oxidative and Psychological Stress, and Cognitive Function in Physically Active Male Adults

A study testing Ashwagandha and Resistance training in people with Strength Training Adaptations and Stress, run by Gdansk University of Physical Education and Sport at 1 site in Poland.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

This clinical trial will study the effects of Ashwagandha (Withania somnifera), a natural plant extract, on physical and mental health in adult men. Ashwagandha is known for its potential to reduce stress, support hormonal balance and improve sleep and physical performance. Read more about this study

Who is it for?
Ages 25 to 40 years, men onlyHealthy volunteers can take part
What is being tested?
Ashwagandha and Resistance training
Type of treatment
Pill or oral medicine
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
1 sitePoland
Study dates
1 Sep 2025to Sep 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 25 to 40 years
  • Men only
  • Healthy volunteers accepted
  • Adult

Who may be able to join

  • Minimum 6 months of consistent resistance training experience
  • Participation in at least two resistance training sessions per week
  • No use of Ashwagandha, adaptogenic supplements, or medications
  • No medical contraindications and signed informed consent

Who cannot join

  • History of cardiovascular events, liver disorders, or psychiatric illness
  • Medical contraindications for participation
  • Use of nicotine products, including e-cigarettes
  • BMI > 29.9, to ensure homogeneity in body composition

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Poland1 site, 1 recruiting
  • Gdansk University of Physical Education and Sport

    Gdansk, Pomeranian Voivodeship, 80-336

    Żaneta Wojdakowska, +48 58 554 71 01, zaneta.wojdakowska@awf.gda.pl

    Recruiting

Other trials in Poland

About this study

This clinical trial will study the effects of Ashwagandha (Withania somnifera), a natural plant extract, on physical and mental health in adult men. Ashwagandha is known for its potential to reduce stress, support hormonal balance and improve sleep and physical performance. The study will explore how taking Ashwagandha for 12 weeks, with resistance training, affects various health markers such as stress hormones, brain function, muscle strength, body composition, sleep quality, and cognitive abilities.

Participants will be healthy, non-smoking men aged 25-40, with regular resistance training experience. They will be randomly assigned to one of two groups: (1) weight training + Ashwagandha, (2) weight training + placebo. The study is double-blinded, meaning neither participants nor researchers will know who is receiving Ashwagandha or placebo.

Read more

Participants will:

  • Take Ashwagandha or a placebo every day for 12 weeks
  • Train in the gym three times a week

Researchers will assess changes in blood markers (like cortisol, testosterone and BDNF - brain-derived neurotrophic factor), physical performance (muscle strength and endurance), sleep quality, stress perception and cognitive function before and after the 12-week period. The goal is to better understand how Ashwagandha works.

Read the detailed description

This randomized, double-blind, placebo-controlled clinical trial aims to investigate the effects of 12-week supplementation with Ashwagandha (Withania somnifera) extract on a range of physiological, biochemical and psychological outcomes in healthy adult males, experienced in resistance training.

Ashwagandha is an adaptogenic herb commonly used to support stress resilience, sleep quality, hormonal balance and physical performance. Although prior studies suggest promising benefits in these areas, current evidence is limited in scope and often lacks methodological rigor. Specifically, there is a scarcity of research examining Ashwagandha's effects in physically active individuals and in combination with structured exercise programs.

The goal of this study is to assess whether Ashwagandha supplementation enhances physiological adaptations to resistance training and/or improves health markers in trained individuals. Researchers will also examine the underlying mechanisms by evaluating hormone levels, neurotrophic factors, oxidative stress, inflammation and their relationship with performance and well-being outcomes.

A total of 40 healthy male participants will be recruited and randomly assigned to one of two groups:

  • Resistance-trained individuals + resistance training + Ashwagandha (n = 20)
  • Resistance-trained individuals + resistance training + placebo (n = 20)

All participants will undergo pre- and post-intervention assessments. Participants will follow a structured resistance training program consisting of three weekly sessions for 12 weeks. Those in the intervention group will receive 400 mg/day of Ashwagandha extract (KSM-66, standardized to 5% withanolides), while control group will receive visually identical placebo capsules.

Primary outcome measures include:

Hormonal and biochemical markers: cortisol, testosterone, IGF-1 - Insulin-like Growth Factor 1, BDNF, and oxidative stress markers (e.g., lipid and protein peroxidation).

Neurocognitive and psychological assessments: cognitive performance (VPT, VFT - Verbal Fluency Test, Stroop Test, TMT-A - Trail Making Test, Part A, TMT-B - Trail Making Test, Part B), perceived stress (PSS-10 - Perceived Stress Scale), and sleep quality (PSQI - Pittsburgh Sleep Quality Index), mood (POMS - Profile of Mood States).

Physical performance: maximal strength (one repetition maximum, 1RM bench press, Biodex), muscular endurance (bench press repetitions to failure at 75% 1RM).

Body composition: skeletal muscle mass and body fat percentage measured via bioelectrical impedance (Seca mBCA 555).

Participants will be monitored for compliance via supplement counts and electronic logs. Dietary intake will be tracked weekly using structured food diaries and analyzed with the Fitatu application. One training session a week will be supervised and logged by certified strength and conditioning coaches, another two will be performed by participants themselves and monitored through an electronic log.

Blood samples will be collected at baseline and post-intervention for hormonal, inflammatory, and oxidative stress analysis. Serum and plasma will be stored at -80°C and analyzed using ELISA and spectrophotometry methods.

The study's main hypotheses are as follows:

Ashwagandha supplementation combined with resistance training will improve hormone profiles (increase testosterone, IGF-1, BDNF; decrease cortisol, stress markers) more than placebo conditions.

Ashwagandha will enhance physical performance (increase maximal strength, muscular endurance, skeletal muscle mass; decrease body fat) beyond that of placebo conditions.

Ashwagandha will reduce perceived stress and improve sleep quality and cognitive function.

Positive correlations are expected between improvements in biomarkers (e.g., BDNF, testosterone) and performance and psychological outcomes.

This study addresses several gaps in the current literature by combining objective physiological and psychological measures, investigating potential mechanisms of action such as oxidative stress and inflammation. Unlike previous research, this trial will examine integrated outcomes rather than isolated variables, allowing for a more comprehensive understanding of Ashwagandha's effects.

Participants will be recruited via social media campaigns and corporate outreach events. Safety monitoring will include weekly contact, adherence checks, and documentation of adverse events. Ashwagandha's safety profile is supported by prior studies using comparable doses (400-600 mg/day), which report low incidence of side effects. Nonetheless, participants may withdraw at any time and will be excluded in the event of injury, illness, or withdrawal of consent.

Ethical approval has been granted, and the study is conducted in accordance with the Declaration of Helsinki. The results are expected to contribute to evidence-based recommendations for adaptogenic supplementation in both trained and general populations. The research team includes experts in physiology, sports nutrition, neuropsychology and clinical supplementation research, ensuring a rigorous and interdisciplinary approach.

By examining how Ashwagandha interacts with physical training and how it affects biological, cognitive and psychological outcomes, this project will help define the contexts in which Ashwagandha can be most effectively used. The study's findings may also have implications for stress management, cognitive health, and performance enhancement strategies in health-conscious or physically active populations.

Being tested
Ashwagandha, Placebo, Resistance training
Keywords
ashwagandha supplementation, resistance training, cognitive functions, stress
Medical subject headings
Sleep Initiation and Maintenance Disorders, Inflammation

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • AshwagandhaDietary supplement

    Also called Withania Somnifera

    A supplement (Ashwagandha, KSM-66 extract, standardized to 5% withanolides content) will be administered in capsule form. Supplement will be taken once a day - 2 capsules (each 200mg of extract) taken 1 hour before sleep, totalling 400 mg of Ashwagandha (20mg of withanolides) a day. The intervention will last 12 weeks.

  • PlaceboDietary supplement

    A placebo (starch, matched to Ashwagandha regarding color and texture) will be administered in capsule form. Placebo will be taken once a day - 2 capsules a day. The intervention will last 12 weeks.

  • Resistance trainingOther

    Also called Strength training

    Participants will follow a standardized, structured, and intensity-adjusted resistance training program consisting of three sessions per week (one supervised, two unsupervised). Training will be conducted under the supervision of a certified strength and conditioning coach. All training sessions will be logged and monitored for adherence.

Study groups in NCT07803068
Study groupRoleWhat they receive
Ashwagandha + resistance trainingExperimentalResistance trained individuals will be supplemented with Ashwagandha (400mg of extract a day) and will undergo a resistance training program, consisted of 3 workouts a week, for 12 weeks.
Receives: Dietary Supplement: Ashwagandha; Other: Resistance training
Placebo + resistance trainingPlacebo comparatorResistance trained individuals will be administered a placebo and will undergo a resistance training program, consisted of 3 workouts a week, for 12 weeks.
Receives: Dietary Supplement: Placebo; Other: Resistance training

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change from Baseline in Maximal strength of upper lower limbs at 12 weeks.

    One-repetition maximum (1RM) in the bench press will be assessed using three attempts with progressively increased loads.

    Units: kilograms (kg)

    Measured: Baseline and 12 weeks.

  2. Change from Baseline in cortisol levels at 12 weeks

    Serum levels of cortisol will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions.

    Units: nmol/l

    Measured: Baseline to 12 weeks

  3. Change from Baseline in BDNF levels at 12 weeks

    Serum levels of BDNF will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions.

    Units: pg/ml

    Measured: Baseline to 12 weeks

Secondary outcomes (12)
  1. Change from Baseline in oxidative stress markers at 12 weeks.

    Spectrophotometric determination of lipid and protein peroxidation products in plasma will be conducted as markers of oxidative damage.

    Measured: Baseline to 12 weeks.

  2. Change from Baseline in visuospatial memory at 12 weeks

    Participants will undergo neuropsychological Visual Patterns Test (VPT) administered by a licensed psychologist to evaluate visuospatial memory. Score will be evaluated as a total score of correctly remembered patterns.

    Measured: Baseline to 12 weeks

  3. Change from Baseline in information processing efficiency at 12 weeks

    Participants will undergo neuropsychological tests (Trail Making Test Part A and Trail Making Test Part B) administered by a licensed psychologist to evaluate information processing efficiency. Scores will be evaluated as completion time and number of mistakes. Shorter time and less mistakes mean better results.

    Measured: Baseline to 12 weeks

  4. Change from Baseline in muscular endurance of upper limbs at 12 weeks.

    Maximum number of repetitions at 75% 1RM in the bench press until failure will be performed.

    Units: number of repetitions

    Measured: Baseline and 12 weeks

  5. Change from Baseline in testostrone levels at 12 weeks

    Serum levels of testosterone will be determined using enzyme-linked immunosorbent assay (ELISA) per the manufacturer's instructions.

    Units: nmol/l

    Measured: Baseline to 12 weeks

  6. Change from Baseline in subjective sleep quality at 12 weeks.

    Participants will fill in a questionnaire Pittsburgh Sleep Quality Index (PSQI). Total scores will be shown on a scale from 0 to 21, with higher scores indicating worse outcomes.

    Measured: Baseline and 12 weeks

  7. Change from Baseline in perceived stress at 12 weeks.

    Participants will fill in a questionnaire Perceived Stress Scale (PSS). Total scores will be shown on a scale from 0 to 40, with higher scores indicating worse outcomes.

    Measured: Baseline and 12 weeks.

  8. Change from Baseline in mood states at 12 weeks.

    Participants will fill in a questionnaire Profile of Mood States (POMS). Total scores will be shown on a Total Mood Disturbance scale from -30 to 200, with higher scores indicating worse outcomes.

    Measured: Baseline and 12 weeks.

  9. Change from Baseline in Maximal strength of lower limbs at 12 weeks.

    Strength will be assesed using the Biodex (Biodex System 4 Pro, NY, USA) with isometric knee extension at 60 degrees of knee extension and knee flexion at 120 degrees of knee extension.

    Measured: Baseline and 12 weeks.

  10. Change from Baseline in working memory and information processing efficiency at 12 weeks

    Participants will undergo neuropsychological Stroop Test administered by a licensed psychologist to evaluate working memory and information processing efficiency. Scores will be evaluated as completion time and number of mistakes. Shorter time and less mistakes mean better results.

    Measured: Baseline to 12 weeks

  11. Change from Baseline in body fat percentage at 12 weeks.

    Body fat percentage will be measured using the Seca mBCA 555 bioimpedance analyzer, which estimates the proportion of fat mass relative to total body weight.

    Units: percentage (%)

    Measured: Baseline and 12 weeks

  12. Change from Baseline in lean body mass at 12 weeks.

    Lean body mass will be measured using the SECA bioimpedance analyzer, which estimates the proportion of lean body mass to total body weight.

    Units: kilograms (kg)

    Measured: Baseline and 12 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Sep 2026
  2. Study start1 Sep 2025
  3. Primary completionMar 2027 (estimated)
  4. Study completionSep 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Basic science
Allocation
Randomised
Intervention model
Parallel groups
Model description
The study will be randomized, double-blind, and placebo-controlled.
Masking
Double blind
Who is masked
Participant, Investigator
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07803068
Sponsor's protocol ID
AWFiS/2025_6_MS
Status last verified
Sep 2026
First submitted
28 Jul 2026
Last updated
3 Sep 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Yes: All collected IPD will be shared.

Questions about this trial

What is this clinical trial studying?

A study testing Ashwagandha and Resistance training in people with Strength Training Adaptations and Stress, run by Gdansk University of Physical Education and Sport at 1 site in Poland.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 3 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Poland. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Each site lists its own contact: choose the nearest one under Trial locations. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change from Baseline in Maximal strength of upper lower limbs at 12 weeks. (time frame: Baseline and 12 weeks.). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Sep 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in